Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6429)
All Articles published online
|
Publishing Process of This Article
|
Feb 6, 2018 (publication date) through Dec 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS. Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. World J Gastrointest Pharmacol Ther 2018; 9(1): 8-13 [PMID: 29430323 DOI: 10.4292/wjgpt.v9.i1.8] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v9/i1/8.htm |
| Number | Citing Articles |
| 1 |
Kathryn Clarkston, Yi‐Ting Tsai, Kimberly Jackson, Michael J. Rosen, Lee A. Denson, Phillip Minar. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. Journal of Pediatric Gastroenterology and Nutrition 2019; 69(1): 68 doi: 10.1097/MPG.0000000000002304
|
| 2 |
Ruben J. Colman, Dana M. H. Dykes, Ana Catalina Arce-Clachar, Shehzad A. Saeed, Phillip Minar. Pediatric Inflammatory Bowel Disease. 2023; : 407 doi: 10.1007/978-3-031-14744-9_31
|